Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Ovid Therapeutics Inc. on June 7, 2019. The company is incorporated in Delaware and its common stock trades on the NASDAQ Global Select Market under the symbol OVID.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to a vote of security holders:
- Proposal 1 (Election of Director): Stockholders elected Bart Friedman to serve a three-year term until the 2022 Annual Meeting.
- For: 20,234,156 votes
- Withheld: 1,817,343 votes
- Broker Non-Votes: 8,483,327 votes
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- For: 30,495,948 votes
- Against: 4,481 votes
- Abstain: 34,397 votes
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement filed on April 24, 2019.
Key Facts for Investor Verification
- Confirmation that Bart Friedman's term begins immediately and extends to the 2022 Annual Meeting.
- Verification of KPMG LLP's engagement for the fiscal year ending December 31, 2019.
- Review of the April 24, 2019 proxy statement for context on the director nominee and auditor selection.